Treatment protocols differ
Combination is not validated No published study has tested whether GHK-Cu, KPV, BPC-157, and TB-500 act synergistically when administered together
The baseline HVPG was higher in AVB than non-AVB group(18.91 mmHg vs 15.78 mmHg p 17.5mmHg predicted LRE(P 30 could help stratify patients who need aggressive surveillance as well as better preventive strategies including dosing of beta-blockers and endoscopy prophylaxis 3163-A SERUM THROMBOSPONDIN 2 AND INSULIN-LIKE GROWTH FACTOR PREDICT ADVANCED LIVER FIBROSIS WITH COMMON VARIABLE IMMUNODEFICIENCY Rambabu Surabattula 1 , Valentina Strohmeier 2 , Anna-Maria Globig 2 , Sudharani Myneni 1 , Maximilian Heeg 2 , Gerhard Kindle 2 , Sigune Goldacker 2 , Caroline Von Spee-Mayer 2 , Michele Proietti 2,3 , Birke Bausch 2 , Dominik Bettinger 2 , Michael Schultheiss 2 , Robert Thimme 4 , Klaus Warnatz 2 and Detlef Schuppan 1,5 , (1)University Medical Center Mainz, (2)University Medical Center Freiburg, (3)Hannover Medical School, (4)University of Freiburg, (5)Harvard Medical School Background: Timely detection of segmental fibrosis and portal hypertension as a manifestation in a significant subgroup of patients with common variable immunodeficiency (CVID) represents a challenge, since it is usually not associated with classical liver cirrhosis
The Future of GHK-Cu Peptide The future looks bright for GHK-Cu peptide research and applications
